SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: tom jones who wrote (2633)7/31/1999 8:39:00 PM
From: Scott H. Davis  Respond to of 4676
 
<<Not much new. Isis said they will spend $14 million to increase 2302 inventory for marketing>> Sounds like they're pretty confidant of the trial success & FDA review. Good news, Scott



To: tom jones who wrote (2633)8/4/1999 11:38:00 PM
From: Scott H. Davis  Read Replies (2) | Respond to of 4676
 
European Approval of Vitravene Triggers $2.5 MM Milestone for Isis
biz.yahoo.com

<<The Committee approved Vitravene(TM) for use in the local treatment of CMV retinitis in newly diagnosed or advanced CMV retinitis when other therapies are considered unsuitable or have been ineffective>>
Sounds like they got 1st line (newly diagnosed)

Milestone, Eoropean & Brazillian revenue too (granted not much volume)
But this helps liquidity. IMSCO Scott


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News